[1] |
Gao Y, Moua T. Treatment of the connective tissue disease-related interstitial lung diseases: a narrative review[J]. Mayo Clin Proc, 2020, 95(3): 554-573.
|
[2] |
黄华, 金燕樑, 丁飞, 等. 儿童结缔组织性疾病相关间质性肺病的诊治进展[J]. 国际儿科学杂志, 2020, 47(11): 768-772.
|
[3] |
唐晓蕾, 李彩凤, 赵顺英. 儿童结缔组织病相关肺损害[J]. 中国循证儿科杂志, 2016, 11(2): 148-156.
|
[4] |
Sgalla G, Iovene B, Calvello M, et al. Idiopathic pulmonary fibrosis: pathogenesis and management[J]. Respir Res, 2018, 19(1): 32.
|
[5] |
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40(9): 1725.
|
[6] |
Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001[J]. J Rheumatol, 2004, 31(2): 390-392.
pmid: 14760812
|
[7] |
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292(7): 344-347.
|
[8] |
Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides[J]. Clin Exp Nephrol, 2013, 17(5): 603-606.
doi: 10.1007/s10157-013-0869-6
pmid: 24072416
|
[9] |
Zulian F, Woo P, Athreya BH, et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis[J]. Arthritis Rheum, 2007, 57(2): 203-212.
|
[10] |
徐雪峰, 蒋敏, 刘秀云, 等. 儿童免疫相关性疾病临床实用热点问题专家建议系列之二——中国儿童结缔组织疾病相关间质性肺病变诊治专家建议[J]. 中国实用儿科杂志, 2020, 35(3): 174-179.
|
[11] |
Jeganathan N, Sathananthan M. Connective tissue disease-related interstitial lung disease: prevalence, patterns, predictors, prognosis, and treatment[J]. Lung, 2020, 198(5):735-759.
doi: 10.1007/s00408-020-00383-w
pmid: 32780179
|
[12] |
王妍华, 蒲丹, 罗静, 等. 147例常见结缔组织病相关间质性肺病的临床特征及转归分析[J]. 西安交通大学学报(医学版), 2019, 40(4): 598-603.
|
[13] |
谢荣华, 吴振彪, 贾俊峰, 等. 305例结缔组织病相关间质性肺病临床特点分析[J]. 临床肺科杂志, 2016, 21(12): 2135-2138.
|
[14] |
Aurangabadkar GM, Aurangabadkar MY, Choudhary SS, et al. Pulmonary manifestations in rheumatological diseases[J]. Cureus, 2022, 14(9): e29628.
|
[15] |
Doshi JA, Mundhra KS, Shah DS,et al, Role of high-resolution CT thorax in diagnosing interstitial lung disease and its association with smoking and connective tissue disorder[J]. Cureus, 2022, 14(11): e31107.
|
[16] |
Huang H, Hu Y, Wu Y, et al. Lung involvement in children with newly diagnosed rheumatic diseases: characteristics and associations[J]. Pediatr Rheumatol Online J, 2022, 20(1): 71.
doi: 10.1186/s12969-022-00731-5
pmid: 35987688
|
[17] |
Mira-Avendano I, Abril A, Burger CD, et al. Interstitial lung disease and other pulmonary manifestations in connective tissue diseases[J]. Mayo Clin Proc, 2019, 94(2): 309-325.
doi: S0025-6196(18)30704-3
pmid: 30558827
|
[18] |
Palmucci S, Galioto F, Fazio G, et al. Clinical and radiological features of lung disorders related to connective-tissue diseases: a pictorial essay[J]. Insights Imaging, 2022, 13(1): 108.
|
[19] |
Hackner K, Stadler A, Schragel F, et al. Transbronchial lung cryobiopsy: prospective safety evaluation and 90-day mortality after a standardized examination protocol[J]. Ther Adv Respir Dis, 2022, 16: 17534666221077562.
|
[20] |
Qiu M, Chen Y, Ye Q. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis[J]. Clin Respir J, 2018, 12(3): 1084-1092.
|
[21] |
Lee JS, Fischer A. Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease[J]. Expert Rev Clin Immunol, 2016, 12(5): 509-520.
|
[22] |
黄莎, 李凡. 结缔组织病相关间质性肺病诊断及治疗的研究进展[J]. 国际呼吸杂志, 2020, 40(15): 1160-1167.
|
[23] |
Nishi K, Ogura M, Tamai N, et al. Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review[J]. Pediatr Rheumatol Online J, 2022, 20(1): 60.
doi: 10.1186/s12969-022-00723-5
pmid: 35927666
|
[24] |
Maruyama Y, Shigemura T, Kobayashi N, et al. Efficacy of tocilizumab for interstitial lung disease associated with polyarticular juvenile idiopathic arthritis[J]. Pediatr Int, 2022, 64(1): e14737.
|
[25] |
Maniscalco V, Marrani E, Rossi E, et al. Too young to fail: a case report on the effectiveness of tocilizumab for paediatric systemic sclerosis-associated interstitial lung disease[J]. Scand J Rheumatol, 2021, 50(6): 491-492.
|